GLOBAL CANCER THERAPEUTICS AND BIOTHERAPEUTICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Cancer therapeutics and biotherapeutics is a large and growing market globally. While conventional treatment options such as chemotherapy have limitations, newer biological and targeted therapies are revolutionizing cancer treatment. Biological therapies harness the power of the human immune system or block cancer cell growth using monoclonal antibodies or other agents. Targeted cancer therapies focus on specific molecular targets found in cancer cells unlike chemotherapy which affects all rapidly dividing normal and cancerous cells. With advances in understanding cancer biology and technological innovations, a wide range of biologics and targeted therapies are being developed and commercialized. These newer therapeutic approaches have improved survival and quality of life for many cancer patients.

Market Dynamics:

The global cancer therapeutics and biotherapeutics market growth is driven by the rising global cancer burden, growing demand for personalized medicine, increasing research funding for cancer drug development, and launch of novel targeted and biological therapies. However, high developmental costs of biologics and targeted drugs along with associated technical challenges are restraining the market growth. Ongoing R&D for newer mechanisms and combination therapies provide opportunities for market expansion.

Key Features of the Study:

- This report provides in-depth analysis of the global cancer therapeutics and biotherapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global cancer therapeutics and biotherapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Roche, Novartis, Pfizer, AstraZeneca, GlaxoSmithKline and AbbVie.

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- The global cancer therapeutics and biotherapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer therapeutics and biotherapeutics market

Detailed Segmentation-

• By Application
  
  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Cervical Cancer
  • Head and Neck Cancer
  • Giloblastoma
  • Malignant Meningioma
  • Mesothelioma
  • Melanoma
  • Others
• By Therapy Type
  
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Radiation Therapy
  • Hormone Therapy
  • Biotherapy
  • Others
• By End User
  
  • Hospitals & Clinics
  • Cancer Care Centers 
  • Research Institutes
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Amgen Inc.
  • Bristol-Myers Squibb
  • Celgene Corporation
  • ELI Lilly and Company
  • Hoffmann-La Roche AG
  • EnGeneIC Ltd
  • Merck & Co Inc.
  • Novartis
  • Pfizer Inc.
  • Johnson & Johnson
  • AstraZeneca
  • Bristol-Myers Squibb
  • Biogen IDEC
  • Sanofi
  • Novartis AG
  • Roche
  • Schering-Plough
  • Gilead Sciences
  • Takeda Pharmaceutical Company